nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Pregnancy/Postpartum"

 

Paternal Prevalence of Comorbid Depression and Anxiety During First Two Years Postpartum
January 4, 2022   

A recent longitudinally cohort study examined the prevalence of paternal comorbid depression and anxiety during the first and second year postpartum and investigated the predictors for comorbidity during the first and second-year following birth...
 Continue reading
Postpartum Anhedonia: Emergent Patterns in Bipolar and Unipolar Depression
December 7, 2021   

Anhedonia, the lack of interest in previously pleasurable activities, is sometimes a symptom of depression and has been associate with worse outcomes. In this study, Gollan and colleagues looked at anhedonia in postpartum women with either unipolar postpartum depression...
 Continue reading
2021 NEI Congress Taking a Bite Out of Nutrition and Mental Health
November 7, 2021   

During the 2021 NEI Congress, Dr. Andrew Cutler presented a fascinating lecture on the influence of nutrition on mental health. He presented metabolic contributors to mental illness, along with an examination of the role that inflammation, and specific diets play in mental health. Possible contributors to mental illness are..
 Continue reading
Scale May Detect More Than Depression in Early Pregnancy
February 8, 2021   

Postpartum depression continues to be prevalent, while early detection methods can help prevent this mental health condition. In a recent study, 2,271 antenatal women participated in a study that tested the efficacy of the Edinburgh Postnatal Depression Scale...
 Continue reading
Offspring of Women With Polycystic Ovary Syndrome Have Increased Risk Of Psychiatric Disorders
September 21, 2020   

A new, a population-based cohort study has found that children who are born to women who are living with polycystic ovary syndrome have an increased risk of psychiatric disorders....
 Continue reading
Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects
August 28, 2020   

Between 6% and 8% of United States pregnant women are prescribed antidepressants. However, concerns remain about the adverse effects of antidepressants on fetal and infant health, including birth defect risk after early pregnancy exposure. The current study addresses this concern by examining the...
 Continue reading
FDA Recalls Extended-Release Metformin Due to Detection of NMDA
June 5, 2020   

The Food and Drug Administration has asked companies to voluntarily recall a specific type metformin over a potential cancer risk. The FDA announced that a high level of N-Nitrosodimethylamine, which is linked to cancer, was found in...
 Continue reading (Members only)
Public Views of Mental Illness Are Increasingly Associated with Violence
October 22, 2019   

In a recent study, trends in public perceptions of violence and support for coerced treatment across a twenty-two-year period were examined. Data was...
 Continue reading (Members only)
Metformin Use During Pregnancy May Affect Growth of Offspring
September 12, 2019   

A recent systematic review and meta-analysis compares metformin to insulin for treatment of gestational diabetes mellitus and how it each may alter the growth trajectories from the time of fetal exposure to childhood. Despite...
 Continue reading (Members only)
FDA Approves First Medication for Postpartum Depression
March 21, 2019   

Postpartum depression (PPD) is an often-debilitating major depressive episode occurring in the postnatal period and affects a significant portion of women (~20% of new mothers). Unfortunately, standard antidepressant treatments are often ineffective for PPD and may leave the mother at risk of causing harm to herself or to her infant. It is therefore exciting news that the FDA has approved the first treatment specifically for PPD...
 Continue reading
1234
Top of Page